Vertex Pharmaceuticals Incorporated

VRTX remains in a constructive long-term uptrend, trading above its 200-day moving average of 449.31 and 50-day average of 459.91. The stock is still below its 52-week high of 533.67, so the regime is strong but not stretched into fresh highs.

Street sentiment stays favorable, with a Buy consensus and a 547.93 average target versus the last close at 485.65. Recent calls have mostly been reaffirmations or target raises, including UBS to 585, Truist to 560, and RBC to 570, while the broader target band still runs from 350 to 616.

The setup leans constructive after Vertex has beaten EPS in 4 of the last 7 quarters, including a 3.8% beat in the most recent reported quarter. Next-quarter estimates point higher, with 2027 EPS consensus at 21.34 versus 2026 TTM EPS of 16.85, so shareholders should watch for continued execution and margin durability.

Recent insider activity leans to net selling, led by repeated discretionary sales from EVP Carmen Bozic and smaller sales from other officers. The award grants to directors are routine compensation noise, but the cluster of S-sale transactions across May and June suggests management has been trimming exposure rather than adding.

Vertex screens as highly profitable, with a 54.4% gross margin, 38.1% operating margin, and 35.5% net margin. Growth remains solid too, with revenue up 7.8% year over year and earnings up 61.4%, while free cash flow reached $4.07 billion on $3.63 billion of operating cash flow.

VRTX stands out for scale, profitability, and balance-sheet strength in biotechnology, backed by $6.61 billion of cash and $2.73 billion of net cash. At 25.8x earnings, it trades at a premium to slower-growth healthcare names, which fits a quality-growth franchise with multiple late-stage programs.